ODTX.US Odyssey Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
19.14 USD
Close of Nov 15, 2026
15.10 29.05
Market cap
USD 920M
P/E
-
P/B
2.45x
ROE
-51.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ODTX.US undervalued?

Graham number

The Graham number of Odyssey Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Odyssey Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Odyssey Therapeutics, Inc. Common Stock yet.

Odyssey Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Odyssey Therapeutics, Inc. Common Stock

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (…

Full company profile